FDA accepts NDA filing for retigabine

ALISO VIEJO, Calif. Valeant Pharmaceuticals announced that the Food and Drug Administration has accepted for review the new drug application for its adjunctive treatment for adult epilepsy patients with partial-onset seizures.

Retigabine is a neuronal potassium channel opener, Valeant said. The drug maker is said retigabine is part of a license and collaboration agreement with GlaxoSmithKline.

Login or Register to post a comment.